Currently, in the minimally invasive treatment of cerebral hemorrhage surgery, the most commonly used fibrinolytic drugs are tissue plasminogen activator (tPA), which can make the formation of blood clots in the brain quickly ablation, so that doctors can clean up as soon as possible. However, it is expensive, which not only brings great economic pressure to patients, but also proves that tPA may cause delayed brain edema and nerve injury.
Urokinase project research, 973, head of the plan's chief scientist, southwest hospital neurosurgery team Feng Hua professor and his team in an academic exchange and data access accidental discovery, a few small hospital and clinical research center had in minimally invasive surgery joint fibrinolytic eliminate using urokinase records in the cerebral hemorrhage, but the lack of relevant data to support. According to professor feng hua, urokinase plasminogen activator (uPA), as a common drug, has been used for many years in China, mainly for thrombolytic therapy of thromboembolic diseases, including acute extensive pulmonary embolism and myocardial infarction, but it has not been used as a major fibrinolytic drug in minimally invasive surgery.
The team realized that urokinase might better focus on how to reduce the volume of intracerebral hematoma in minimally invasive surgery and protect the neural tissue in the brain. According to this idea, professor feng hua and his team have conducted more than two years of specific research.
"In this study, we used the classic 'intracerebral autologous blood injection' to simulate human intracerebral hemorrhage, and used uPA and tPA as minimally invasive fibrinolytic agents to remove intracerebral hematomas, respectively." Professor feng hua said.
The results showed that uPA and tPA injection both effectively reduced the volume of intracerebral hematoma, but uPA better reduced the cerebral edema around the hematoma, and protected the blood-brain barrier tight junction protein and intracerebral nerve function, thereby improving the success rate of surgery.
Feng hua said that his research team will conduct large animal models and clinical trials to further verify the safety and effectiveness of uPA in the treatment of cerebral hemorrhage, and the findings are expected to provide new ideas and methods for neurosurgeons to treat cerebral hemorrhage and other diseases.